TaiMed Biologics Inc (中裕新藥) could receive US approval for its new HIV/AIDS drug TMB355 before the end of next year, Yuanta Securities Investment Consulting Co (元大投顧) said on Tuesday, citing a positive outcome of the drug’s phase II trials.
In addition, the company is to introduce an intramuscular variant of the drug, which is estimated to have a larger potential market than the intravenous version, Yuanta analyst Peggy Lee (李珮菁) said in a client note.
Other drugs the company has in the pipeline include TMB365, a monoclonal antibody, and TMB607, a small-molecule protease inhibitor, which are due to start clinical trials next year, she said.
The company plans to submit a biological product license application to the administration before the end of this year, which would grant the new drug an expedited review timetable.
The US Food and Drug Administration (FDA) has put TMB355 on its Breakthrough Therapy Designation and Fast Track lists.
“We have been in close contact with the US FDA in an effort to reduce the number of test patients required for phase-three trials from 300 to 30, which would bring expenses down to less than US$5 million from between US$50 million and US$60 million,” TaiMed president and CEO James Chang (張念原) said at an investors’ conference early this month.
Chang said that the drug disrupts HIV entry into CD4 T lymphocyte cells without interfering with immune functions.
“HIV/AIDS patients need to be on medication for the rest of their lives and many develop resistance to drugs following prolonged treatment,” Chang said.
According to Yuanta, the FDA has agreed to conduct rolling reviews for the new drug and its final review is scheduled to be completed within six months.
“We are upbeat on the company’s phase-three clinical trials for intravenous TMB355, which could be approved by the FDA toward the end of next year,” Lee said in the note.
The new drug is expected to be used by between 8,000 and 12,000 patients per year by 2019, with one year’s treatment costing between US$40,000 and US$50,000, she said.
TaiMed is expected to top US$130 million in net profits next year, she added.
TaiMed shares closed at NT$202 yesterday in Taipei trading, a rise of 75 percent from its Monday initial public offering price of NT$115.
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure